Luis G Paz-Ares

Summary

Publications

  1. pmc PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
    Purificacion Estevez-Garcia
    Instituto de Biomedicina de Sevilla IBIS HUVR, CSIC, Universidad de Sevilla, Sevilla, Spain
    BMC Cancer 12:514. 2012
  2. doi request reprint PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Luis G Paz-Ares
    Servicio de Oncologia Medica, University Hospital Virgen del Rocio, Av Manuel Siurot s n 41013 Seville, Spain
    J Clin Oncol 31:2895-902. 2013
  3. doi request reprint A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
    Luis Paz-Ares
    Department of Medical Oncology, IBIS and Hospital Universitario Virgen del Rocio CSIC Universidad de Sevilla, Servicio de Oncologia, Seville, Spain
    J Thorac Oncol 8:329-37. 2013
  4. doi request reprint Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
    Luis G Paz-Ares
    Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Investigaciones Biomédicas de Sevilla, Avenida Manuel Siurot s n, Seville, Spain 41013
    J Clin Oncol 30:3084-92. 2012
  5. pmc Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advan
    Luis G Paz-Ares
    University Hospital Virgen del Rocio, Seville, Spain
    BMC Cancer 10:85. 2010

Collaborators

Detail Information

Publications5

  1. pmc PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
    Purificacion Estevez-Garcia
    Instituto de Biomedicina de Sevilla IBIS HUVR, CSIC, Universidad de Sevilla, Sevilla, Spain
    BMC Cancer 12:514. 2012
    ..VEGFR and PDGFR are key players involved in this process. The purpose of this study was to assess the incidence of genetic variants in these receptors and its potential clinical implications in colorectal cancer (CRC)...
  2. doi request reprint PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Luis G Paz-Ares
    Servicio de Oncologia Medica, University Hospital Virgen del Rocio, Av Manuel Siurot s n 41013 Seville, Spain
    J Clin Oncol 31:2895-902. 2013
    ....
  3. doi request reprint A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
    Luis Paz-Ares
    Department of Medical Oncology, IBIS and Hospital Universitario Virgen del Rocio CSIC Universidad de Sevilla, Servicio de Oncologia, Seville, Spain
    J Thorac Oncol 8:329-37. 2013
    ..This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC)...
  4. doi request reprint Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
    Luis G Paz-Ares
    Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Investigaciones Biomédicas de Sevilla, Avenida Manuel Siurot s n, Seville, Spain 41013
    J Clin Oncol 30:3084-92. 2012
    ..This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC)...
  5. pmc Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advan
    Luis G Paz-Ares
    University Hospital Virgen del Rocio, Seville, Spain
    BMC Cancer 10:85. 2010
    ....